About Venrock
Venrock is a venture capital firm founded in 1969. It is primarily based out of Palo Alto, United States. As of Sep 2025, Venrock is an active investor, having invested in 31 companies, with 2 new investments in the last 12 months. It primarily invests in Post IPO round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Environment Tech. Most recently it participated in the $***** Post IPO round of Maze Therapeutics Overall, Venrock portfolio has seen 15 IPOs and 4 acquisitions including key companies like Verastem, RayzeBio and Century Therapeutics. A lot of funds co-invest with Venrock, with names like Boxer Capital sharing a substantial percentage of its portfolio. Venrock has team of 55 people including 21 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Post IPO, Series B & 4 more
Portfolio IPOs
Portfolio Acquisitions
Deals in last 12 months
Venrock's List of Top Investments
Venrock has a portfolio of 31 companies. Their most notable investments are in Sojournix and Upstream Bio.Their portfolio spans across United States, Canada, Ireland and 3 more locations. They have invested in Life Sciences, High Tech, Environment Tech and 5 other sectors, across stages such as Post IPO, Series B and 4 more. Here is the list of top investments by Venrock:
1. Verastem
Developer of small molecule inhibitors of signaling pathways for cancer therapy. The company focuses on developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation, Focal Adhesion Kinase (FAK), PI3K/mTOR, and Wnt.
Key facts about Verastem
- Founded Year: 2010
- Location: Needham (United States)
- Annual Revenue: $30.9M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $68.5M
- Employee Count: 147 as on Apr 30, 2026
- Investors: BVF Partners, Venrock and 18 Others
- Latest Funding Round: Post IPO, Apr 25, 2025, $*****
- Highlight: Public
2. RayzeBio
Key facts about RayzeBio
- Founded Year: 2019
- Location: San Diego (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $426M
- Employee Count: 258 as on Apr 30, 2026
- Investors: Venrock, Wellington and 21 Others
- Latest Funding Round: Series D, Aug 25, 2022, $*****
- Highlight: Acquired
Developer of therapeutics for the treatment of autoimmune diseases and cancer. The company's iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development and manufacturing capabilities to generate allogeneic, iPSC-derived therapies for autoimmune diseases and cancer.
Key facts about Century Therapeutics
- Founded Year: 2018
- Location: Philadelphia (United States)
- Annual Revenue: $109M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $410M
- Employee Count: 106 as on Apr 30, 2026
- Investors: Boxer Capital, Fidelity Investments and 22 Others
- Latest Funding Round: Post IPO, Jan 08, 2026, $*****
- Highlight: Public
Developer of therapeutics to treat acute myeloid leukemia. The company has developed cancer therapeutics using engineered hematopoietic stem cells (eHSC). The company's lead candidate includes VOR33 which targets CD33 protein in cancer patients to treat acute myeloid leukemia (AML).
Key facts about Vor Biopharma
- Founded Year: 2019
- Location: Cambridge (United States)
- Stage: Public
- Total Funding till date: $152M
- Employee Count: 103 as on Mar 31, 2026
- Investors: HTIF, Venrock and 10 Others
- Latest Funding Round: Post IPO, Dec 15, 2025, $*****
- Highlight: Public
Developer of drugs for solid tumors and blood cancers. It offers precision oncology therapeutics which include ELVN-001, a small molecule kinase inhibitor that target the BCR-ABL gene fusion, andELVN-002 a HER2 inhibitor with activity against various HER2 mutations for non-small cell lung cancer and solid tumors.
Key facts about Enliven Therapeutics
- Founded Year: 2019
- Location: Boulder (United States)
- Stage: Public
- Total Funding till date: $140M
- Employee Count: 75 as on Apr 30, 2026
- Investors: Boxer Capital, Fidelity Investments and 15 Others
- Latest Funding Round: Post IPO, Mar 21, 2024, $*****
- Highlight: Public
Venrock's Year-on-Year Investment Trends
Venrock has invested in 31 companies over the last 11 years, with an average of 3 new investments annually in the last 10 years. In 2025, it made 2 investments. Its most recent first time investment was in Maze Therapeutics and most recent follow-on round was in Taysha Gene Therapies.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 2 | 0 | 2 |
2024 | 7 | 0 | 7 |
2023 | 4 | 1 | 5 |
2022 | 2 | 0 | 2 |
2021 | 5 | 1 | 6 |
2020 | 5 | 0 | 5 |
2019 | 2 | 0 | 2 |
2018 | 1 | 0 | 1 |
2017 | 1 | 0 | 1 |
Venrock's Investments by Stage
Venrock has made 12 investments in Post IPO stage with an average round size of $112M, 9 investments in Series B stage with an average round size of $105M and 5 investments in Series A stage with an average round size of $163M.Stage of entry | No. of Investments |
|---|---|
Post IPO | 12 |
Series B | 9 |
Series A | 5 |
Series C | 2 |
PE | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Venrock's Investments by Sector
Venrock has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Sustainability Tech, Healthcare and Consumer. Notably, it has invested in 29 Enterprise (B2B) companies, 29 Tech companies, 2 Software companies and 1 company focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 28 |
High Tech | 5 |
Sustainability Tech | 4 |
Healthcare | 2 |
Consumer | 1 |
Others | 3 |
Note: We have considered here, only first round of investments
Venrock's Investments by Geography
Venrock has made most investments in United States (24), followed by Canada where it has made 2 investments.Country | No. of Investments |
|---|---|
United States | 24 |
Canada | 2 |
Ireland | 2 |
China | 1 |
France | 1 |
Note: We have considered here, only first round of investments
Venrock's recent investments
Venrock has not made any investment in 2026 so far.Here are the most recent investments by Venrock:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 11, 2025 | United States | Post IPO | 5109 | ||
Jun 25, 2025 | United States | Post IPO | 1785 | ||
Oct 25, 2024 | Canada | Post IPO | 3247 | [+5] | |
2024 | United States | Seed | 6859 | ||
May 07, 2024 | United States | Series A | 7080 |
IPOs and Publicly Listed companies in Venrock's Portfolio
15 of Venrock's portfolio companies have become public. Maze Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jan 2025 at marketcap of $700M and Upstream Bio got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $873M.Here are Venrock's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jan 31, 2025 | Sep 11, 2025 | Post IPO | 8683 | |
Oct 11, 2024 | Jun 08, 2023 | Series B | 3620 | |
Nov 01, 2023 | Oct 25, 2024 | Post IPO | 9651 | |
Jul 29, 2021 | May 11, 2021 | Series B | 5665 | |
Jun 25, 2021 | Apr 12, 2021 | Series B | 3678 |
Acquired companies in Venrock's Portfolio
4 companies from Venrock's portfolio have been acquired. The most recent acquisition was Centessa Pharmaceuticals in Mar 2026 by Lilly for $*****.Here are Venrock's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 31, 2026 | Feb 16, 2021 | Series A | 5996 | |
Oct 22, 2025 | Feb 21, 2020 | Post IPO | 9367 | |
Dec 26, 2023 | Nov 23, 2020 | Series B | 5209 | |
Jun 02, 2021 | Oct 01, 2019 | Post IPO | 6606 |
Team profile of Venrock
Venrock has a team of 55 members including 21 Partners and 11 Principals located in United States and Sri Lanka. Venrock's team does not sit on the board of any company as of now.Here is a list of top team members in Venrock:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | New York City | - | ||
Partner | New York City | - | ||
Partner | New York City | - | - | |
Partner | - | - | - | |
Partner | - | - | - | |
Partner | Palo Alto | - | ||
Partner | - | - | - | |
Partner | Mountain View | - | ||
Partner | Palo Alto | - | - | |
Partner | Menlo Park | - | ||
Partner | Menlo Park | - |
Co-investors of Venrock
Over the past 11 years, 236 investors have co-invested in Venrock's portfolio companies. This includes funds and angels.
- Invested before Venrock: Orbimed, Casdin Capital and 91 others have invested in rounds before Venrock. There are 5 companies where Orbimed has invested before Venrock and 4 companies where Casdin Capital has invested before Venrock.
- Top Co-investors of Venrock: 98 investors entered a company along with Venrock. These include investors like Boxer Capital (9 companies).
- Invested after Venrock: A total of 45 investors have invested in Venrock's portfolio after their investments. Top Investors include Venrock (5 companies), TCG Crossover (4 companies) and RTW Investments (3 companies).
Recent News related to Venrock
•
Timberlyne Therapeutics Raises $180M in Series A FundingFinSMEs•Jan 10, 2025•Timberlyne, Abingworth, Bain Capital Life Sciences, Venrock and 6 others
•
Sublingual psychedelic startup nets $60M for depression trialsFiercepharma•Nov 08, 2022•Lusaris Therapeutics, RA Capital Management, Venrock, Boxer Capital and 1 other
•
•
Annexon Announces $130 Million Private Placement FinancingGlobeNewswire•Jul 08, 2022•Annexon, Redmile Group, Adage Capital Management, Bain Capital Life Sciences and 6 others
•
•
•
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for CancerPipelinereview•Jun 16, 2021•RayzeBio, Venrock, Perceptive Advisors, Vivo Capital and 13 others
•
Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell TherapiesBusiness Wire•Feb 26, 2021•Artiva, Venrock, Acuta Capital Partners, EcoR1 and 12 others
•
Lianbio Leaps To $310mGlobal Corporate Venturing•Oct 30, 2020•LianBio, Pfizer, RA Capital Management, SDIC and 14 others
•
Kinnate Biopharma Closes $98 Million Series C FinancingBusiness Wire•Aug 26, 2020•Kinnate Biopharma, RA Capital Management, Viking Global Investors, Venrock and 13 others
